BLUEJETBlue Jet Healthcare Limited
Pharma · Biotechnology · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Blue Jet Healthcare Limited engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for use in pharmaceutical and healthcare products. It provides contrast media intermediates; niche pharmaceutical intermediates and APIs; and CDMO/CMO services, as well as end-to-end solutions from process development and commercialization of NCEs, advance intermediates, API, and building blocks. The company develops, manufactures, and markets saccharin and related salts. It has operations in India, Norway, France, the United States, Italy, Sweden, and internationally. Blue Jet Healthcare Limited was incorporated in 1968 and is headquartered in Thane, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on BLUEJET — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why avoid
- • Overall evidence is weak (AlgoScore 39/100)
- • Revenue growth: -31.1% YoY
- • Profit growth: -41.5% YoY
- • RSI: 29
- • MACD: bearish
Bull case
- • ROE: 19.9%
- • ROCE: 19.3%
- • Debt/Equity: 0.03
- • Golden cross setup: SMA50 above SMA200
Bear case
- • Revenue growth: -31.1% YoY
- • Profit growth: -41.5% YoY
- • RSI: 29
- • MACD: bearish
Key risks
- • Momentum is fading versus the broader market
- • Revenue growth: -31.1% YoY
- • Profit growth: -41.5% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹17.52). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.